Welcome to
Breckenridge Pharmaceutical, Inc.

 

Breckenridge Pharmaceutical, Inc. is a Towa Company. 

 TOWA PHARMACEUTICAL CO.,LTD.

We are an own label distributor that performs pharmaceutical marketing, sales and distribution in the U.S.  The company was founded in 1983 and markets a broad range of generic prescription products in several therapeutic categories and dosage forms, including tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders, transdermal patches, and injectable products.

The Breckenridge label is recognized nationwide by wholesalers, distributors, chains, managed care accounts, and retail pharmacies.

Breckenridge, headquartered in Berlin, Connecticut, markets products under more than 40 Abbreviated New Drug Applications (ANDAs) approved by the Food and Drug Administration (FDA).                                    

 

 

Latest News

Breckenridge Announces Final Approval of its ANDA for Everolimus Tablets (generic for Afinitor®)

Mar 08,2021

Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Everolimus Tablets (generic for Afinitor®). This product was developed in collaboration with Natco Pharma Limited. According to industry sales data, Afinitor and its therapeutic equivalents generated annual sales of $712 million during the twelve months ending December 2020.  Breckenridge plans to launch Everolimus Tablets in 2.5mg, 5mg and 7.5mg strengths during the second quarter of 2021 in a blister card packaging configuration. Breckenridge’s launch of the product’s 10mg strength is based on terms that are presently confidential and will be announced at a later date. 

 About Breckenridge:

Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and lives of the patients we and our customers serve.

www.bpirx.com

About Natco:

Natco Pharma Limited is a global generic pharmaceutical research, development, manufacturing and marketing company. The company was established in 1981 in India. Natco supplies pharmaceutical products to over 50 countries across the globe, including the United States. Natco focuses on the development and manufacturing of oncology and other specialty pharmaceuticals.

Read More >>

Breckenridge Announces Final Approval of its ANDA for Asenapine Sublingual Tablets, 5 mg Strength (generic for Saphris®)

Mar 08,2021

Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Asenapine Sublingual Tablets in 5mg strength (generic for Saphris®). Breckenridge plans to launch this strength immediately. Breckenridge previously launched the product's 2.5mg and 10mg strengths and will now market all three strengths. This product was developed in collaboration with MSN Laboratories Private Limited. According to industry sales data, Saphris® generated annual sales of $233 million during the twelve months ending December 2020.

 

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and lives of the patients we and our customers serve.

www.bpirx.com

 

About MSN:

MSN Group is the fastest growing research based pharmaceutical company headquartered in India. Founded in 2003 with a mission to make health care affordable, MSN has nine API and five finished dosage facilities in Hyderabad and the U.S. The Group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals. With its core focus on speed and consistency in delivery, MSN has achieved more than 650 national and international patents, is world no. 1 in active U.S. DMF filings, has a product portfolio featuring over 380 APIs and over 250 formulations covering over 35 major therapies and has won the trust of more than 40,000,000 customers across 65 countries worldwide.

Read More >>

Breckenridge Announces Final Approval of its ANDA for Asenapine Sublingual Tablets, 2.5 and 10mg Strengths (generic for Saphris®)

Dec 11,2020

Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Asenapine Sublingual Tablets in 2.5mg and 10mg strengths (generic for Saphris®).  Breckenridge plans to launch these strengths immediately.  Additionally, the U.S. Food and Drug Administration granted tentative approval for the 5mg strength. This product was developed in collaboration with MSN Laboratories Private Limited. According to industry sales data, Saphris® generated annual sales of $239 million during the twelve months ending September 2020.

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and lives of the patients we and our customers serve.

www.bpirx.com

About MSN:

MSN Group is the fastest growing research based pharmaceutical company headquartered in India. Founded in 2003 with a mission to make health care affordable, MSN has nine API and five finished dosage facilities in Hyderabad and the U.S. The Group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals. With its core focus on speed and consistency in delivery, MSN has achieved more than 650 national and international patents, is world no. 1 in active U.S. DMF filings, has a product portfolio featuring over 380 APIs and over 250 formulations covering over 35 major therapies and has won the trust of more than 40,000,000 customers across 65 countries worldwide.

Read More >>

Product Search

All brand names are registered trademarks of their respective owner(s).